Baicalein inhibits renal cancer cell growth and metastasis via ERK and p38 pathway

作者：Zhaoxin Guo, Tianyu Liu, Renguang Lv, Yongzhen Zhang, Liwei Meng, Zunlin Zhou, Zhaoxu Liu, Lei Yan · 发表于：Research Square · 年份：2022 · DOI：10.21203/rs.3.rs-1847253/v1 · 被引用次数：2 · 研究领域：Flavonoids in Medical Research、Computational Drug Discovery Methods、Cancer Mechanisms and Therapy

Abstract Background Baicalein has exhibited anti-tumor effects against several cells of different origins. However, the potential effects of baicalein on renal cancer has not been investigated. Methods Human A498 and 786-O cell lines were used to investigate the antirenal acitivity of baicalein. CCK-8 assay was used to detect cell viability. Cell migration was assessed by scratch assay and transwell migration assay in vitro. Transwell invasion assay was carried out to evaluate the effect of baicalein on cell invasion. Apoptosis assay was performed to detect cell apoptosis using the Annexin V-FITC/PI apoptosis detection kit. The protein expression of ERK, p-ERK, p38, p-p38, p53, bax, bcl-2 and survivin were measured by WB assay. Results Baicalein significantly inhibited the proliferation of A498 and 786-O cells in a time- and dose-dependent manner. The similar effect of baicalein on cell migration, invasion and cell apoptosis were observed. Mechanismlly, ERK and p38 MAPK pathways account for the anti-tumor effects of baicalein. Conclusions Baicalein can induce apoptosis and inhibit metastasis of renal caner cells through inhibition of the ERK and p38R pathway.